Charles River Laboratories (CRL)

• Market cap: $9.5B
• 1 day: 1.99%
• 5 days: -2.08%
• 1 month: -1.13%
• 3 months: -9.73%
• 6 months: -11.38%
• Year to date: -20.70%
• 1 year: -19.80%
• 5 years: 22.48%
• 10 years: 190.67%
• Sector: Industrials
• Industry: Commercial Physical & Biological Research

About: Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.

Employees: 21,400

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

2.51% less ownership

Funds ownership: 102.93% [Q2] → 100.42% (-2.51%) [Q3]

6% less funds holding

Funds holding: 657 [Q2] → 617 (-40) [Q3]

7% less capital invested

Capital invested by funds: $10.9B [Q2] → $10.2B (-$782M) [Q3]

25% less funds holding in top 10

Funds holding in top 10: 8 [Q2] → 6 (-2) [Q3]

26% less repeat investments, than reductions

Existing positions increased: 199 | Existing positions reduced: 268

38% less first-time investments, than exits

New positions opened: 66 | Existing positions closed: 106

38% less call options, than puts

Call options by funds: $59M | Put options by funds: $94.8M

Research analyst outlook

7 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $151 19% downside
• Avg. target: $201 8% upside
• High target: $250 35% upside

7 analyst ratings

• positive: 1 14%
• neutral: 3 43%
• negative: 3 43%

B of A Securities Derik De Bruin 32% 1-year accuracy 6 / 19 met price target	13% upside $210	Neutral Maintained	13 Dec 2024
TD Cowen Charles Rhyee 22% 1-year accuracy 2 / 9 met price target	22% upside $227	Hold Maintained	11 Nov 2024
UBS Dan Brennan 48% 1-year accuracy 14 / 29 met price target	35% upside $250	Buy Maintained	7 Nov 2024
Evercore ISI Group Ross Muken 0% 1-year accuracy 0 / 5 met price target	21% upside $225	In-Line Maintained	7 Nov 2024
CLSA	10% downside $167	Underperform Initiated	23 Oct 2024